U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Buying a new pharmacy will allow Hims & Hers to expand into new markets. Hims & Hers ( HIMS -1.11%) recently acquired a ...

We recently compiled a list of the 10 Best Hair Care Stocks To Buy Now. In this article, we are going to take a look at where ...

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.

Check the time stamp on this data. Updated AI-Generated Signals for Hims & Hers Health Inc. Class A (HIMS) available here: ...

Hims & Hers, the telehealth company, saw its stock price range from under $6 to over $25 during the last 52 weeks. Click here ...

The biggest news was Hims & Hers issuing 976,341 shares of common stock to acquire Nivagen Pharmaceuticals, which does ...

Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military ...

Analysts believe Hims & Hers will earn $0.57 per share this year and $0.80 next year. That prices the stock at 17 times next ...

Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer, Target, and Teladoc Health. The Motley Fool recommends Johnson & Johnson, Moderna, ...